The global anesthesia drugs market was valued at $6.8 billion in 2020.
By 2028, it will be worth $8.93 billion, having grown at a compound annual growth rate of nearly 3.5%, according to a report from Strategic Market Research.
The report forecasts that general anesthesia drugs will dominate this market during the period in question, and key players will include AbbVie (NYSE: ABBV), Aspen Pharmacare (JSE: APN) AstraZeneca (LSE: AZN), Baxter International (NYSE: BAX) and Boehringer Ingelheim.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze